Cargando…
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study
Autores principales: | Schönlein, Martin, Wrage, Victoria, Ghandili, Susanne, Mellinghoff, Sibylle C., Brehm, Thomas Theo, Leypoldt, Lisa B., Utz, Nils, Schrader, Roland M., Alsdorf, Winfried, Börschel, Niklas, Bußmann, Lara, Schönrock, Martin, Perlick, Dorothea, Schön, Gerhard, Verpoort, Karl, Lütgehetmann, Marc, Schulze zur Wiesch, Julian, Weisel, Katja C., Bokemeyer, Carsten, Schafhausen, Philippe, Sinn, Marianne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040439/ https://www.ncbi.nlm.nih.gov/pubmed/35512712 http://dx.doi.org/10.1016/j.ccell.2022.04.016 |
Ejemplares similares
-
OAB-049: Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment
por: Ghandili, Susanne, et al.
Publicado: (2021) -
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
por: Ghandili, Susanne, et al.
Publicado: (2021) -
CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients
por: Ghandili, Susanne, et al.
Publicado: (2021) -
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
por: Ghandili, Susanne, et al.
Publicado: (2021) -
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
por: Ghandili, Susanne, et al.
Publicado: (2022)